CBG Found to Trigger Multiple Cancer Cell Death Pathways in Pancreatic Tumor Cells
- New research shows that cannabigerol (CBG) exhibits strong anti-cancer effects against pancreatic cancer cells by slowing cell growth and inducing multiple forms of programmed cell death.
- CBG causes cell cycle arrest in the G1 phase, stopping pancreatic cancer cells from multiplying, and promotes apoptosis by increasing key apoptotic proteins like cleaved caspase-3, caspase-9, and PARP1.
- CBG also triggers ferroptosis, an iron-dependent form of cell death, by altering gene networks linked to this pathway and activates the unfolded protein response, particularly the IRE1α-XBP1 axis, which is vital to its cytotoxic effects.
- The study highlights a novel mechanism where CBG drives both apoptosis and ferroptosis via ER stress-linked signaling, suggesting its potential as a therapeutic agent targeting pancreatic cancer vulnerabilities.
New research published in Free Radical Biology and Medicine found that cannabigerol (CBG) may have strong anti-cancer effects against pancreatic cancer cells, with researchers saying the compound slowed cell growth and triggered multiple forms of programmed cell death. The study was conducted by researchers from Kangwon National University and the Korean Pharmacopuncture Institute, who examined how CBG affects human pancreatic cancer cells. While CBG has already drawn attention for its anti-inflammatory, antibiotic and anticancer potential, the researchers said its effects on pancreatic cancer had not been established prior to this analysis.
According to the study, CBG produced a “potent antiproliferative effect” in pancreatic cancer cells by causing cell cycle arrest in the G1 phase, effectively stopping the cells from continuing to multiply. The compound also promoted programmed cell death through apoptosis, a process the body uses to eliminate damaged or dangerous cells.
The researchers found that CBG increased proteins associated with apoptosis, including cleaved caspase-3, caspase-9 and PARP1, while also raising the proportion of apoptotic cells overall. Beyond that, transcriptomic profiling showed that CBG altered gene networks tied not only to apoptosis, but also ferroptosis, another type of cell death linked to iron-dependent oxidative damage.
The study says CBG also activated a major stress-response system inside cells known as the unfolded protein response. In particular, it triggered the IRE1α-XBP1 axis, which the researchers identified as a central part of how the compound exerts its effects. When that pathway was blocked using a small-molecule inhibitor, CBG’s cytotoxic impact was substantially reduced.
Researchers also found that CBG changed the expression of ferroptosis-related genes and proteins including DDIT3, NFE2L2, HMOX1, CHOP, NRF2 and HO-1. They say the findings show a previously unknown mechanism through which CBG may attack pancreatic cancer cells by driving both apoptosis and ferroptosis through ER stress-linked signaling.
The researchers conclude that these findings support CBG’s potential as a therapeutic agent for targeting ER stress-related vulnerabilities in pancreatic cancer.